📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

DXC Technology Company, together with its subsidiaries, provides information technology services and solutions in the United States, the United Kingdom, the Rest of Europe, Australia, and internationally. It operates through three segments: Consulting & Engineering Services, Global Infrastructure Services, and Insurance Software & Services. The Consulting & Engineering Services segment delivers software engineering, consulting, and custom and enterprise application solutions; focusing on AI and data analytics to enhance operations and support digital transformation across industries such as finance, automotive, manufacturing, healthcare, life sciences, travel, and the public sector. The Global Infrastructure Services segment provides design, migration, and management of data center, mainframe, cloud, and network environments. This segment also provides cross-industry business process services, which streamline clients’ core enterprise functions such as finance, HR, procurement, and customer service. The Insurance Software & Services segment offers software and business process services for life and wealth, property and casualty, and reinsurance providers to modernize and digitally transform their operations. The company markets and sells its products through a direct sales force to commercial businesses and public sector enterprises. DXC Technology Company has a multi-year global alliance with Anthropic to bring AI into mission-critical enterprise systems; and strategic partnership with ElevenLabs to accelerate AI-first transformation strategy by embedding advanced voice AI capabilities across its internal operations and customer solutions. DXC Technology Company was founded in 1959 and is headquartered in Ashburn, Virginia.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

📊 MIXED DXC Q4 FY2026 revenue $3.1B, margin 7.6%, guides FY2027 revenue decline 3-5%

Revenue & Profitability

Fourth quarter revenue was $3.1 billion, down 6.6% year-over-year. Adjusted EBIT margin was 7.6% (up 30 bps YoY), non-GAAP EPS $0.77, and free cash flow $110 million. Full-year revenue was $12.6 billion, down 4.8% YoY; adjusted EBIT margin 7.7%, non-GAAP EPS $3.23, free cash flow $713 million. Guidance for fiscal 2027: organic revenue decline 3-5%, adjusted EBIT margin 6-7%, non-GAAP EPS $2.40-2.90, free cash flow ~$600 million.

Outlook

Management expects continued macro uncertainty and weakness in discretionary project-based services throughout fiscal 2027. They do not assume any improvement in the macro environment in their guidance. They note that customers are pausing large technology decisions to evaluate AI-native alternatives, which is causing delays but is a normal phase of a major technology wave.

Growth Drivers

Growth levers include Fast Track AI solutions (CoreIgnite, OASIS) that are recurring, scalable, and platform-agnostic; insurance software (high teens growth in Q4, driven by cloud migrations and AI Smart Apps); and improved win rates in large competitive deals. GIS growth is expected to improve in the second half of FY2027 as headwinds from prior contract losses roll off.

Balance Sheet & CapEx

Free cash flow guidance of ~$600 million for fiscal 2027 reflects lower adjusted EBIT, partially offset by working capital benefits. The company continues to invest in offering development, sales, and marketing. Capital leases are being reduced. Specific CapEx guidance was not provided.

Margins

Adjusted EBIT margin guidance for fiscal 2027 is 6-7%, down from 7.7% in fiscal 2026, due to revenue decline and investments offsetting one-time benefits. First quarter margin is expected to be ~5% (lowest of the year), with sequential improvement through Q2 and Q3 before moderating in Q4. AI-driven productivity in outcome-based contracts (80% of revenue) provides a long-term margin expansion lever.

Key Risks

Risks flagged include continued weakness in discretionary project-based spending, macro deterioration (which would push revenue to the low end of guidance), execution challenges in converting pipeline to revenue, and delays in large technology decisions due to AI evaluation. Inability to improve win rates on large deals could also pressure growth.

Generated by AI · Q4 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q1 2027 Q1 2027 2026-07-30

Revenue declined 6.7% year-over-year to $3B, but bookings rose 5% and free cash flow was strong, aided by a litigation benefit. Leadership changes and AI-driven solutions are accelerating innovation and shortening sales cycles, with guidance reaffirmed for improved margins and cash flow in FY27.

Q4 2026 Q4 2026 2026-05-07

Q4 profitability and free cash flow exceeded guidance, but revenue declined due to weak discretionary spending, especially in GIS. FY 2027 guidance anticipates further revenue decline but margin stability, with AI-driven offerings and cost efficiencies expected to support future growth.

Q3 2026 Q3 2026 2026-01-29

Q3 revenue declined 4.3% year-over-year to $3.2B, with strong free cash flow and margin above guidance. AI-driven Fast-Track initiatives are ahead of schedule, and capital allocation remains disciplined, with continued investments and share repurchases.

Q2 2026 Q2 2026 2025-10-30

Q2 saw strong free cash flow and margins above guidance, but revenue and bookings lagged, prompting a focus on execution and pipeline conversion. Fast Track AI initiatives and new products are expected to drive future growth, with improved cash flow guidance and continued investment in innovation.

Q1 2026 Q1 2026 2025-07-31

Q1 results met or exceeded guidance, with strong bookings growth and improved free cash flow. Segment performance was mixed, with CES and GIS declining but Insurance growing. FY26 guidance was raised for EPS and revenue, and AI investments are driving operational and client transformation.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.